Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Adenocarcinoma Previously Treated With Gemcitabine

NCT00099294 is registered in ClinicalTrials.gov with Threshold Pharmaceuticals as lead sponsor.

NCT NCT00099294
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00099294 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Adenocarcinoma Previously Treated With Gemcitabine
Lead sponsor
Threshold Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2004
Completion date
January 31, 2007
Enrollment
300
Sites
111

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer